Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY

被引:0
作者
Anita Boyapati
Jérôme Msihid
Stefano Fiore
Janet van Adelsberg
Neil M. H. Graham
Jennifer D. Hamilton
机构
[1] Regeneron Pharmaceuticals,
[2] Inc.,undefined
[3] Sanofi R&D,undefined
[4] Sanofi US,undefined
来源
Arthritis Research & Therapy | / 18卷
关键词
Sarilumab; Rheumatoid arthritis; Biomarker; RANKL/OPG;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 207 条
[1]  
Schett G(2005)Mechanisms of disease: the link between RANKL and arthritic bone disease Nat Clin Pract Rheumatol 1 47-54
[2]  
Hayer S(2010)Rheumatoid arthritis Lancet 376 1094-108
[3]  
Zwerina J(2000)The links between joint damage and disability in rheumatoid arthritis Rheumatology (Oxford) 39 122-32
[4]  
Redlich K(2010)The role of interleukin 6 in the pathophysiology of rheumatoid arthritis Ther Adv Musculoskelet Dis 2 247-56
[5]  
Smolen JS(1988)Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides Arthritis Rheum 31 784-8
[6]  
Scott DL(1990)IL-6 is produced by osteoblasts and induces bone resorption J Immunol 145 3297-303
[7]  
Wolfe F(1996)Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation J Bone Miner Res 11 88-95
[8]  
Huizinga TW(1999)Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products Bone 24 381-5
[9]  
Scott DL(2008)IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17 Rheumatology (Oxford) 47 1635-40
[10]  
Pugner K(1993)Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6 Proc Natl Acad Sci U S A 90 11924-8